Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 7/20 | 0.41 |
| ▸ | PTGER2 | P43116 | 7/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | RARB | P10826 | 6/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | RARA | P10276 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4234086 | 0.88 | PTGER4 (0.44) | PTGER4PTGER2HRH3ALDH1A1 | |
| SCHEMBL4233494 | 0.81 | RARB (0.48) | PTGER4PTGER2RARBALDH1A1MEN1 | |
| SCHEMBL4237159 | 0.81 | S1PR1 (0.47) | PTGER4PTGER2NAMPTHRH3ALDH1A1 | |
| SCHEMBL4228610 | 0.79 | NAMPT (0.57) | NAMPTALDH1A1MAPT | |
| SCHEMBL4238905 | 0.76 | NAMPT (0.39) | NAMPTRARBALDH1A1MAPT | |
| Terephthalic Acid SCHEMBL4612225 | 0.67 | TSHR (0.67) | RARBALDH1A1PPARAMEN1RARA | |
| SCHEMBL70166 | 0.67 | TSHR (0.67) | RARBALDH1A1PPARAMEN1RARA | |
| SCHEMBL10900440 | 0.67 | EBP (0.51) | PTGER4PTGER2HRH3MEN1KMT2A | |
| SCHEMBL4233519 | 0.67 | SIGMAR1 (0.53) | NAMPTKMT2A | |
| SCHEMBL104594 | 0.66 | GRIN2D (0.57) | RARBALDH1A1MEN1RARAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | PTGER4 467/4885PTGER2 600/4885NAMPT 2126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.